Uzbekistan today offers one of the most dynamic and strategically positioned pharmaceutical markets in Eurasia, according to Abdulla Azizov, Chairman of the Medical and Pharmaceutical Industry Development Agency and the First Deputy Minister of Health of the Republic of Uzbekistan. The combination of strong political commitment, rapid regulatory modernization, large-scale industrial infrastructure development, and direct government support for investors differentiates Uzbekistan from many other emerging markets.
Azizov shares that over the past several years, the President of the Republic of Uzbekistan has prioritized pharmaceutical industry development as a strategic national objective, resulting in substantial reforms aimed at localization, technology transfer, Good Manufacturing Practices (GMP) alignment, and export-oriented manufacturing. Investors benefit from a rapidly growing domestic market, competitive production costs, preferential conditions within special industrial zones, and direct access to the broader Central Asian and CIS markets.
Uzbekistan’s goal is to build a vertically integrated pharmaceutical and biotechnology ecosystem encompassing production, R&D, education, clinical research, and innovation. This long-term vision, combined with Uzbekistan’s strategic geographic location between Europe and Asia, creates a highly attractive platform for international pharmaceutical companies seeking regional expansion.
The development of Bio Pharma City as a large-scale integrated ecosystem combining manufacturing, education, and R&D is a flagship initiative. Bio Pharma City represents a new-generation pharmaceutical and biotechnology cluster designed as a fully integrated ecosystem rather than a traditional industrial park.
Biotechnology Hub Emerges
Biotechnology is becoming one of the central pillars of Uzbekistan’s long-term pharmaceutical strategy. Globally, the pharmaceutical industry is rapidly transitioning toward biologics, personalized medicine, advanced therapies, and innovative biotechnology-driven solutions. Uzbekistan recognizes this transformation and aims to position itself as a regional biotechnology hub in Central Asia.
Read Also: India adopts AI in healthcare services
Priority subsectors currently include biosimilars development and manufacturing, plasma-derived and blood products, monoclonal antibodies, biotechnology-based diagnostics, regenerative medicine, and advanced biopharmaceutical production technologies. The development of biotechnology infrastructure within Bio Pharma City reflects Uzbekistan’s intention to move beyond traditional generic manufacturing toward higher-value pharmaceutical innovation.
The Agency is taking an approach toward building a sustainable pharmaceutical R&D ecosystem that includes significant investments in scientific and innovation infrastructure, strengthening cooperation with international universities and research institutions, and creating favorable conditions for multinational companies to establish R&D activities in Uzbekistan.
Uzbekistan is undertaking significant reforms to align its pharmaceutical regulatory framework with international standards and best practices, including strengthening GMP and GDP compliance systems, modernizing pharmacovigilance mechanisms, digitalizing regulatory procedures, and improving transparency and efficiency in product registration processes.
Particular attention is being paid to international cooperation and institutional capacity building, including engagement related to PIC/S alignment and inspector training. Uzbekistan is also working to enhance the quality management systems of its regulatory and inspection bodies to build greater international confidence.
Regulatory Reforms Advance
Regulatory modernization is essential not only for investor confidence but also for ensuring the safety, quality, and competitiveness of pharmaceutical products manufactured in Uzbekistan. The government aims to significantly increase exports and position Uzbekistan as a regional pharmaceutical hub, supplying over 50 countries.
Over the next decade, Uzbekistan aims to become one of the leading pharmaceutical manufacturing and distribution hubs in the broader Central Asian and CIS region. Due to its geographic location, Uzbekistan has strong logistical potential to serve neighboring markets efficiently.
Read Also: AES Panels Earn FM 4882 Approval for Cleanrooms
The Agency’s role is evolving from a sector-specific industrial body into a broader strategic institution supporting the development of healthcare, pharmaceuticals, biotechnology, and medical technologies in a coordinated manner. This transformation is expected to create stronger connections between healthcare delivery, industrial development, innovation, and investment attraction.
Following a recent Presidential Decree, the Agency has officially been renamed as the Medical and Pharmaceutical Industry Development Agency under the Ministry of Health of the Republic of Uzbekistan. This institutional transformation reflects the Government’s broader strategic vision for the integrated development of both the pharmaceutical and medical sectors.
They are working to enhance the quality management systems of their regulatory and inspection bodies to build greater international confidence. Abdulla Azizov notes that the development of Bio Pharma City is a key part of this effort.
Uzbekistan’s strategic geographic location between Europe and Asia creates a highly attractive platform for international pharmaceutical companies seeking regional expansion. The government aims to significantly increase exports and position Uzbekistan as a regional pharmaceutical hub.
The Agency’s efforts to build a sustainable pharmaceutical R&D ecosystem are key for the development of the pharmaceutical industry in Uzbekistan. They are creating favorable conditions for multinational companies to establish R&D activities in Uzbekistan.
Biotech Infrastructure Grows
Biotechnology infrastructure within Bio Pharma City is being developed to support the growth of the biotechnology sector in Uzbekistan. The development of biosimilars, plasma-derived and blood products, and monoclonal antibodies are priority areas.
Read Also: Foreign CMOs Boost US Pharma Capacity
Uzbekistan is working to digitalize regulatory procedures and improve transparency and efficiency in product registration processes. This will help to build greater international confidence in the Uzbekistan pharmaceutical industry.
The government’s goal is to make Uzbekistan a leading pharmaceutical manufacturing and distribution hub in the region. They are working to create a favorable business environment and attract investment to the pharmaceutical sector.
Abdulla Azizov believes that the development of the pharmaceutical industry in Uzbekistan has the potential to drive economic growth and improve public health. The Agency is working to support the development of the pharmaceutical industry and create a sustainable ecosystem for pharmaceutical R&D.
The development of the pharmaceutical industry in Uzbekistan is a key part of the government’s strategy for economic development. The Agency is working to create a favorable business environment and attract investment to the pharmaceutical sector.
Uzbekistan’s pharmaceutical industry has the potential to become a major player in the regional market. The government’s efforts to support the development of the industry and create a sustainable ecosystem for pharmaceutical R&D are key for its success.
